Optimizing Treatment of HER2-Positive Breast Cancer
This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Illustrate evidence-based systemic treatment recommendations for patients with breast cancer based on HER2-receptor status
William J. Gradishar, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician